India, Nov. 4 -- UroGen Pharma Ltd. (URGN), reported higher third-quarter 2026 revenue, driven by continued growth in ZUSDURI sales. The company also announced regulatory and clinical progress across its pipeline and lowered its full-year 2026 JELMYTO revenue outlook.
Company Profile
UroGen develops and commercializes innovative treatments for urothelial cancers.
Its commercial portfolio includes ZUSDURI, a mitomycin-based treatment for recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer (LG-IR-NMIBC), and JELMYTO, a treatment for low-grade upper tract urothelial cancer (LG-UTUC).
Q3 Financial Highlights
For the third quarter ended September 30, 2026, total revenue increased to $89.0 million from $27.5 million in t...